PHP
HALO icon

Parkman Healthcare Partners’s Halozyme HALO Stock Holding History

Parkman Healthcare Partners’s Portfolio HALO Stock Details HALO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-41,333
Closed -$1.66M – 84
2021
Q4 		$1.66M Buy
+41,333
New +$1.54M 0.37% 65
2020
Q2 		– Sell
-50,466
Closed -$908K – 80
2020
Q1 		$908K Sell
50,466
-114,534
-69% -$2.17M 0.42% 56
2019
Q4 		$2.92M Buy
+165,000
New +$2.86M 0.84% 40

Other funds holding HALO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCM
Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Parkman Healthcare Partners's HALO Position: Q1 2022 in Review

Parkman Healthcare Partners sold out of Halozyme (HALO) in Q1 2022, closing a stake of 41,333 shares — an estimated $1.66M sold.

Parkman Healthcare Partners first reported a position in HALO in Q4 2019 and held it in 3 quarters. The position peaked at $2.92M in Q4 2019. 317 funds tracked by Wall St. Rank hold HALO as of Q1 2022.

  • Parkman Healthcare Partners reported no remaining Halozyme position as of Q1 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 41,333 Halozyme shares in Q1 2022, an estimated $1.66M.
  • Parkman Healthcare Partners first reported a position in Halozyme in Q4 2019 and held it in 3 quarters.
  • Parkman Healthcare Partners's Halozyme position peaked at $2.92M in Q4 2019.
  • 317 funds tracked by Wall St. Rank held Halozyme as of Q1 2022.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.